HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imdahl, A. Articles by Hasse, J. Search for Related Content PubMed PubMed Citation Articles by Imdahl, A. Articles by Hasse, J. Related Collections Lung - cancer Lung - other

Eur J Cardiothorac Surg 2001;20:324-329
© 2001 Elsevier Science NL

Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions

^a Department of Thoracic Surgery, Universitätsklinikum Freiburg, Hugstetterstrasse 55, D-79106 Freiburg, Germany
^b Department of Radiology, Division of Nuclear Medicine, University of Freiburg, Freiburg, Germany

Received 11 October 2000; received in revised form 8 May 2001; accepted 14 May 2001.

Corresponding author. Tel.: +49-761-2702401; fax: +49-761-2702499
e-mail: imdahl{at}chir.ukl.uni-freiburg.de

Objective: The impact of the (2-(fluorine-18)-fluoro-2-2deoxy-D-glucose)-positron emission tomography (¹⁸F-FDG-PET) for discrimination of pulmonary lesions was evaluated in a single centre prospective study. Methods: In the study, 109 patients with pulmonary lesions of unknown origin verified by computed tomography were enrolled consecutively (April 1999–May 2000). They were subject to ¹⁸F-FDG-PET diagnostics. ¹⁸F-FDG-PET images were interpreted by two independent nuclear medicine physicians who were blinded to the results of other imaging procedures. In 87 patients, surgery was applied followed by histological investigation, which served as the gold standard. In 22 other patients, extensive tumour load or assumed benign dignity of the lesions prevented surgery. Results: Overall sensitivity of ¹⁸F-FDG-PET in 87 resected patients was 0.86. Differentiation in malignant (n=69) and benign lesions (n=18) revealed sensitivities of 0.9 and 0.72, respectively. Sensitivity of ¹⁸F-FDG-PET in inflammatory lesions was markedly lower (0.43) than in benign tumours (0.91). Standard uptake values were significantly increased in malignant tumours compared with benign lesions (9.9 and 1.6, respectively; P=0.035). There was a clear correlation of sensitivity with tumour size with a failure rate of 27% in lesions 1 cm (n=15), 10% (n=20) in lesions between 1 and 2 cm and 12% (n=45) above 2 cm. In primary bronchial carcinoma, a clear correlation of sensitivity was observed with regard to tumour grading (G1, three out of five; G2, 24 out of 27; G3, 26 out of 26; and G4, one out of one). Lymph node involvement was correctly suggested in 10 out of 19 (52.6%) patients. However, false positive lymph node enhancement was indicated in one out of 18 (5.5%) operated patients with benign lesions and eight out of 39 (20.5%) with bronchial carcinoma. Conclusion: ¹⁸F-FDG-PET at present does not serve as the gold standard for early detection of small and well-differentiated tumours. However, it contributes efficiently to the detection of malignancy in tumours >1 cm, which are moderately or poorly differentiated. Positive lymph node imaging must not preclude surgery but requires histological proof. Discrimination of benign and malignant pulmonary tumours by ¹⁸F-FDG-PET appears to be hampered in inflammatory lesions.

Key Words: Pulmonary lesion • FDG-PET • Tumour grading • Tumour size

This article has been cited by other articles:

				Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767. [Abstract] [Full Text] [PDF]

				J. H. O, I. R. Yoo, S. H. Kim, H. S. Sohn, and S. K. Chung Clinical Significance of Small Pulmonary Nodules with Little or No 18F-FDG Uptake on PET/CT Images of Patients with Nonthoracic Malignancies J. Nucl. Med., January 1, 2007; 48(1): 15 - 21. [Abstract] [Full Text] [PDF]

				A. S. Bryant and R. J. Cerfolio The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann. Thorac. Surg., September 1, 2006; 82(3): 1016 - 1020. [Abstract] [Full Text] [PDF]

				K.-i. Watanabe, H. Nomori, T. Ohtsuka, T. Naruke, A. Ebihara, H. Orikasa, K. Yamazaki, K. Uno, T. Kobayashi, and T. Goya [F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 403 - 409. [Abstract] [Full Text] [PDF]

				H. Nomori, N. Kosaka, K. Watanabe, T. Ohtsuka, T. Naruke, T. Kobayashi, and K. Uno 11C-Acetate Positron Emission Tomography Imaging for Lung Adenocarcinoma 1 to 3 cm in Size With Ground-Glass Opacity Images on Computed Tomography Ann. Thorac. Surg., December 1, 2005; 80(6): 2020 - 2025. [Abstract] [Full Text] [PDF]

				R. M. Lindell, T. E. Hartman, S. J. Swensen, J. R. Jett, D. E. Midthun, M. A. Nathan, and V. J. Lowe Lung Cancer Screening Experience: A Retrospective Review of PET in 22 Non-Small Cell Lung Carcinomas Detected on Screening Chest CT in a High-Risk Population Am. J. Roentgenol., July 1, 2005; 185(1): 126 - 131. [Abstract] [Full Text] [PDF]

				H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno Visual and Semiquantitative Analyses for F-18 Fluorodeoxyglucose PET Scanning in Pulmonary Nodules 1 cm to 3 cm in Size Ann. Thorac. Surg., March 1, 2005; 79(3): 984 - 988. [Abstract] [Full Text] [PDF]

				H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, T. Kobayashi, and K. Uno Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 396 - 401. [Abstract] [Full Text] [PDF]

				E. M. Rohren, T. G. Turkington, and R. E. Coleman Clinical Applications of PET in Oncology Radiology, May 1, 2004; 231(2): 305 - 332. [Abstract] [Full Text] [PDF]

				H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1087 - 1092. [Abstract] [Full Text] [PDF]

				M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 879 - 892. [Abstract] [Full Text] [PDF]

				Y. Funakoshi, N. Sawabata, S.-i. Takeda, Y. Okumura, M. Hayakawa, and H. Maeda Bronchoscopically undiagnosed small peripheral lung tumors Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 517 - 520. [Abstract] [Full Text] [PDF]